• Best practices
  • Best practice: Extensive sharing of IP assets with third-par...
Best practice

Extensive sharing of IP assets with third-party researchers

Company:

Takeda

What:

Sharing high-value IP assets with third-party researchers developing products for diseases in scope of the Index.

Region:

Global

Aim:

To enable swifter development and adaptation of products suited to the needs of people living in low- to middle-income countries.

Context:

Much of the research and development (R&D) into new medicines and vaccines undertaken by pharmaceutical companies is done in-house.

Much of the R&D into new medicines and vaccines undertaken is done in house. However, companies also have the option to share their intellectual property (IP) assets with third-party researchers. This underutilised approach can enable swifter development and adaptation of products and provide benefits for people living in low and middle-income countries.

What makes this a best practice?
When it comes to sharing IP assets, Takeda represents best practice. Of all its peers, it has established the largest number of IP-sharing agreements with many research institutions and product development partnerships (PDPs).

Overall, Takeda shares 18 assets through nine different IP-sharing agreements. Research institution partners include the University of California, San Diego, and the University of California, San Francisco, with whom Takeda shares IP assets for neglected tropical diseases (NTDs) such as schistosomiasis. With the University of Melbourne and National Institutes of Health, Takeda shares assets for malaria. Through its agreement with the University of British Columbia, it shares assets relating to tuberculosis.

Takeda also shares IP assets with a range of PDPs, including the Drugs for Neglected Diseases initiative (DNDi), the Medicines for Malaria Venture (MMV) and the TB Alliance. Another partner is PATH, an NGO whose mission is to eliminate health inequalities and improve health globally.

Through these agreements, third-party researchers conducting R&D for neglected diseases are able to deploy Takeda’s IP assets, which include molecule libraries, patented compounds, processes and technologies.


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |